Beyond Generics: India’s Pharma Industry Reinvents Itself For Global Dominance

The Indian pharmaceutical sector, long recognized for its generics dominance, is now shifting gears toward innovation-driven growth. Industry leaders emphasize that without robust R&D pipelines and strategic capital infusion, Indian drugmakers risk losing ground in the race for global leadership.  

Key Highlights  

• Indian pharma must pivot from generics to innovation-driven growth  
• R&D investment is critical for biologics, specialty drugs, and novel therapies  
• Capital infusion and partnerships will drive infrastructure and talent development  
• Policy support on regulation and IP rights can boost competitiveness  
• Global expansion hinges on innovation pipelines and strategic scaling  

Sources: Business Standard, Economic Times, Mint